Until 2020, only four FDA-approved drugs for AD were shown to provide a modest benefit in symptom management but not to halt disease progression: donepezil, galantamine, rivastigmine, and memantine (the first three are inhibitors of the acetylcholinesterase (AChE) enzyme [17] and the latter is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist [19]). This evidence concerns the gene ACHE and Alzheimer disease.